Table 2 Patient characteristics and... | American Society of Hematology

Table 2

Patient characteristics and response to decitabine treatment

Patient no.	Age, y	Sex	Gene mutation							Eventual clinical outcome
Patient no.	Age, y	Sex	NPM1	FLT3-ITD	CEBPA	DNMT3A	TET2	IDH1	IDH2	Eventual clinical outcome
1	73	F	MUT	WT	WT	WT	MUT	WT	WT	Non-CR
3	69	F	MUT	WT	WT	MUT	WT	WT	WT	CR
4	80	M	WT	WT	WT	WT	WT	WT	WT	Non-CR
5	85	M	WT	WT	WT	WT	WT	MUT	WT	CR
6	71	M	WT	WT	WT	WT	WT	WT	WT	Non-CR
7	84	F	WT	WT	WT	WT	WT	WT	WT	Non-CR
8	66	F	WT	WT	WT	WT	WT	WT	WT	CR
14	80	F	WT	WT	WT	ND	ND	WT	WT	CR
15	75	F	WT	WT	WT	WT	WT	WT	WT	CR
17	74	F	WT	WT	WT	WT	WT	WT	MUT	CR
18	74	M	MUT	WT	WT	WT	WT	WT	WT	CR
19	73	F	WT	WT	WT	WT	WT	MUT	WT	Non-CR
20	81	M	WT	WT	WT	WT	MUT	WT	WT	CR
21	76	M	WT	WT	WT	WT	WT	WT	WT	Non-CR
23	67	M	WT	WT	WT	WT	WT	WT	WT	Non-CR
24	68	M	MUT	WT	WT	MUT	WT	WT	WT	CR

Patient no.	Age, y	Sex	Gene mutation							Eventual clinical outcome
Patient no.	Age, y	Sex	NPM1	FLT3-ITD	CEBPA	DNMT3A	TET2	IDH1	IDH2	Eventual clinical outcome
1	73	F	MUT	WT	WT	WT	MUT	WT	WT	Non-CR
3	69	F	MUT	WT	WT	MUT	WT	WT	WT	CR
4	80	M	WT	WT	WT	WT	WT	WT	WT	Non-CR
5	85	M	WT	WT	WT	WT	WT	MUT	WT	CR
6	71	M	WT	WT	WT	WT	WT	WT	WT	Non-CR
7	84	F	WT	WT	WT	WT	WT	WT	WT	Non-CR
8	66	F	WT	WT	WT	WT	WT	WT	WT	CR
14	80	F	WT	WT	WT	ND	ND	WT	WT	CR
15	75	F	WT	WT	WT	WT	WT	WT	WT	CR
17	74	F	WT	WT	WT	WT	WT	WT	MUT	CR
18	74	M	MUT	WT	WT	WT	WT	WT	WT	CR
19	73	F	WT	WT	WT	WT	WT	MUT	WT	Non-CR
20	81	M	WT	WT	WT	WT	MUT	WT	WT	CR
21	76	M	WT	WT	WT	WT	WT	WT	WT	Non-CR
23	67	M	WT	WT	WT	WT	WT	WT	WT	Non-CR
24	68	M	MUT	WT	WT	MUT	WT	WT	WT	CR

FLT3-ITD indicates internal tandem duplication of the FLT3 gene; CR, complete remission (no disease and full blood count recovery); and Non-CR, noncomplete remission.